Health spending watchdog says donanemab ‘does not currently demonstrate value for the NHS’

A new Alzheimer’s drug has been rejected for widespread use in the health service in England after the health spending watchdog said that it “does not currently demonstrate value for the NHS”.

The news comes as the UK’s medicines regulator said donanemab could be licensed for use in the UK.